Drug Profile
Research programme: anti-CD73 checkpoint inhibitors - Innate Pharma
Alternative Names: anti-CD73 antibodies; anti-huCD73 - Innate Pharma; IPH 53Latest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator Innate Pharma
- Developer Innate Pharma; Paoli-Calmettes-institute
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action 5-nucleotidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for preclinical development in Cancer in France (Parenteral)
- 16 Nov 2021 Innate Pharma plans a phase I trial for the treatment of cancer in collaboration with the Paoli-Calmettes institut
- 07 Oct 2019 Innate Pharma plans clinical trials of IPH 5301 for Cancer